Wednesday, April 03, 2019 11:21:10 AM
Oppenheimer comments...
Celsion Corporation (CLSN) reported 4Q18 and provided a business update to investors last Friday. In focus, CLSN is approaching two interim analyses for ThermoDox from the fully-enrolled Phase 3 OPTIMA study expected in 3Q19 and 2020. We are encouraged by the DMC's December 18, 2018 assessment, highlighting a median PFS of 21.2 months as of the October 4th data cut-off. In addition, the earlier-stage OVATION II with GEN-1 continues to progress, enrolling patients for dose selection and safety. With 2018 year-end cash of $27.7 million, CLSN has ample runway to reach these meaningful potential value-creating catalysts, in our view. We remain bullish.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM